T ranscatheter aortic valve implantation (TAVI) is a widely accepted procedure for the treatment of severe aortic valve stenosis in patients with high operative risk. 1 The minimally invasive nature and excellent clinical outcome of TAVI have led to a widespread use of this procedure. 2 However, several early complications after TAVI have been increasingly recognized as major drawbacks of this procedure and may affect the long-term outcome. 3 Despite these limitations, clinicians are expanding the use of TAVI also into patients with intermediateand low-operative risk. 4,5 A recent randomized trial, the Nordic Aortic Valve Intervention Trial (NOTION), demonstrated that in patients with a mean European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) of ≈2.0%, TAVI achieved 1-year results similar to surgical aortic valve replacement (SAVR). 6 However, this study randomized only 18% of the screened patients and was likely underpowered. Three observational studies showed similar survival after TAVI and SAVR in intermediate-risk patients, 7-9 whereas a recent analysis showed lower early mortality after SAVR with sutureless prosthesis compared with TAVI in patients with a mean EuroSCORE II of ≈4%. 10
TAVI Compared With SAVR in Low-Risk Patients
The aim of the present study is to evaluate the early and 3-year outcome after TAVI and SAVR in low-risk patients (EuroSCORE II <4%) from the multicenter nationwide prospective Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) study.
Methods

Study Design and Data Collection
OBSERVANT is a national observational, prospective, multicenter, cohort study that enrolled consecutive patients undergoing TAVI or SAVR for severe aortic valve stenosis at 93 Italian cardiology/cardiac surgery centers between December 2010 and June 2012. Details on the study design, patient eligibility criteria, and data collection modalities have been reported elsewhere. 9 This study was coordinated by the Italian National Institute of Health and led in cooperation with the Italian Ministry of Health, the National Agency for Regional Health Services, Italian Regions, and Italian scientific societies and federations representing Italian professionals involved in the management of aortic valve stenosis. The complete list of executive working group, participating centers, and investigators is reported in the Appendix in the Data Supplement. In the participating hospitals, both SAVR and TAVI could be offered to patients with aortic valve stenosis. The study protocol has been approved by the Ethical Committee of each participating center, and patients gave their informed consent to participate in this study.
Inclusion Criteria
The study population included consecutive adult patients admitted with a diagnosis of severe aortic valve stenosis (defined as an aortic valve area <1 cm 2 , maximum aortic velocity >4 m/s, or mean pressure gradient >40 mm Hg) and requiring an aortic valve replacement. Data on demographic characteristics, health status before intervention, comorbidities, and complete information on the type of intervention were collected into a standardized online datasheet on a passwordprotected website. Collected data were stored and analyzed at the Italian National Institute of Health. CoreValve (Medtronic, MN) and Sapien XT (Edwards Lifesciences, Irvine, CA) valve prostheses were implanted in these patients.
Patients with EuroSCORE II <4% 11 were the subjects of the present analysis. To evaluate only low-risk patients avoiding any selection bias in the assignment to TAVI or SAVR, patients with porcelain aorta, hostile chest, active endocarditis, and oxygen therapy and thoseundergoing any combined procedure (coronary revascularization or intervention on other heart valves), as well as patients who underwent emergency procedure, were excluded from this analysis.
Data Quality Assessment
Data auditing was performed by independent observers after specific standard operating procedures. They monitored the participating hospitals to assess the completeness of the enrolled cohort and compared the collected data with those of the original clinical records.
Outcomes and Follow-Up
Three-year survival was the primary outcome of this analysis. Secondary outcomes were 30-day mortality and in-hospital adverse events, such as stroke, vascular complications, severe bleeding, and acute kidney injury. Stroke was defined as any focal deficit lasting >24 hours or focal deficit lasting <24 hours with positive neuroimaging studies. Vascular complications were defined as any access site complication requiring surgical or percutaneous vascular intervention. Severe bleeding was defined as bleeding requiring >4 red blood cell units. 12 Acute kidney injury was classified into 3 stages according to the Acute Kidney Injury Network (AKIN) definition criteria and taking into consideration only the baseline and postoperative serum creatinine levels. 13 Other secondary outcomes were major adverse cardiac and cerebrovascular events (MACCE) at 3 years. MACCE were defined as the composite end point including any of the following adverse events: death from any cause, stroke, myocardial infarction, percutaneous coronary intervention, and coronary artery bypass graft. An administrative follow-up has been set up for each enrolled patient through a record linkage with the National Hospital Discharged Records database for in-hospital events and with the Tax Registry Information System for information on survival.
Statistical Analysis
Continuous variables are presented as the mean±standard deviation and were compared using the Student t test. Categorical variables are presented as counts and percentages and were compared with the χ 2 test or Fisher exact test when appropriate. As observational studies do not provide randomization, a propensity score-matching method was used to select 2 groups of patients undergoing SAVR and TAVI, respectively, with similar baseline characteristics. The propensity score was estimated using a nonparsimonious logistic regression model with the treatment method as the dependent variable. 14 The following variables have been included as covariates: age; sex; frailty status; previous percutaneous coronary intervention; previous balloon aortic valvuloplasty; previous cardiac surgery; previous operation on the aorta; chronic dialytic treatment; diabetes mellitus; chronic obstructive pulmonary disease; previous myocardial infarction; peripheral arteriopathy; estimated glomerular filtration rate; critical preoperative state; unstable angina; neurological dysfunction; pulmonary hypertension (systolic pulmonary arterial pressure >60 mm Hg); chronic liver disease; active neoplastic disease; New York Heart Association class; left ventricular ejection fraction; coronary artery disease; urgent operation; and mitral valve regurgitation.
One-to-one propensity score matching was performed using the nearest neighbor method and a caliper of 0.2 of the standard deviation of the logit of the propensity score. 15 When a patient of a pair is lost to follow up and the matched patient is still alive (or free from events when considering the MACCE outcome), the time of observation of both patients is truncated at the time of the last observation of the lost patient to guarantee the comparability between the 2 groups.
To evaluate the balance between the matched groups, the t test for paired sample for continuous variables, the McNemar test for dichotomous variables, the Stuart-Maxwell test for categorical variables, and the analysis of the standardized differences after matching have been used ( Table 1 ). The same tests have been used to test differences in the early adverse events of propensity score-matched groups. Differences in the outcomes of matched pairs at 3 years
WHAT IS KNOWN
• TAVI is widely recognized as an effective treatment method in high-risk patients with severe aortic valve stenosis.
• The excellent results of TAVI are leading to the expansion of its indications toward lower-risk patients, without evidence of any benefit over surgical aortic valve replacement.
WHAT THE STUDY ADDS
• This prospective study showed that surgical aortic valve replacement and TAVI can be performed in patients with EuroSCORE <4% with similar 30-day mortality rates.
• Surgical aortic valve replacement had significantly better 3-year outcomes than TAVI.
• These data suggest that expanding the use of TAVI in low-risk patients may not be justified. TAVI Compared With SAVR in Low-Risk Patients have been evaluated by the Kaplan-Meier method with the Klein-Moeschberger stratified log-rank test. 16 A subgroup analysis of the 3-year mortality among SAVR and TAVI propensity-matched patients has been made stratifying by the following variables: sex, age (≤80 versus >80), previous cardiac surgery, mitral valve regurgitation, left ventricular ejection function, paravalvular leak, new pacemaker, and chronic obstructive pulmonary disease. A Cox model able to account for propensity score matching has been used for each stratified analysis. In case of discordant classification of patients within a pair, because of residual variation in baseline variables, we gave precedence to the characteristics of the TAVI patient. 8 The risk of experiencing a morbid event has been presented by subgroup as hazard ratio with 95% confidence interval. These hazard ratios have been accompanied by test for interaction between treatment and patient characteristics from Cox model.
A Cox regression analysis on the overall low-risk population, adjusting by propensity score, has been performed to assess the robustness of the findings from the propensity-matched SAVR/TAVI groups.
Tests were 2-sided, and a P<0.05 was considered statistically significant. Statistical analyses were performed using the SAS statistical package, version 9.2 (SAS Institute Inc, Cary, NC).
Results
The OBSERVANT study includes 7618 patients who underwent either isolated TAVI or isolated SAVR. For the purposes of this study, 3402 patients (44.7%) fulfilled the inclusion criteria and were the subjects of this analysis. Their baseline characteristics are summarized in Propensity score matching resulted in 355 pairs of patients whose baseline and echocardiographic characteristics are summarized in Tables 1 and 2 . Figure 1 shows the changes in standardized differences in baseline covariates between 
Outcomes
Early outcome end points are reported in Table 3 . Thirtyday mortality was 2.9% after SAVR and 2.6% after TAVI (P=0.82). Stroke rate was rather low and similar in the 2 study groups (SAVR 1.1% versus TAVI 1.1%; P=1.00). The rates of cardiac tamponade (4.3% versus 1.7%; P=0.049), permanent pacemaker implantation (12.7% versus 2.6%; P<0.001), major vascular damage (7.6% versus 0%; P<0.001), mildto-severe paravalvular regurgitation (48.2% versus 11.3%; P<0.001), and moderate-to-severe paravalvular regurgitation (9.7% versus 1.5%; P<0.001) were significantly higher after TAVI compared with SAVR. On the other hand, TAVI was associated with significantly lower risk of cardiogenic shock (1.7% versus 4.6%; P=0.025), severe bleeding (4.4% versus 15.2%; P<0.001), and acute kidney injury (AKIN stages 1-3: 26.0% versus 43.7%; P<0.001) compared with SAVR. TAVI was associated with lower mean transvalvular gradient (10.6 versus 14.4 mm Hg; P<0.001).
One-, 2-, and 3-year survival were 92.2%, 87.2%, and 83.4% after SAVR and 88.6%, 80.4%, and 72.0% after TAVI, respectively (stratified log-rank test; P<0.001; Figure 2 ). One-, 2-, and 3-year freedom from MACCE were 89.6%, 84.6%, and 80.9% after SAVR and 84.6%, 75.9%, and 67.3% after TAVI, respectively (stratified log-rank test; P<0.001; Figure 2 ). Incidence of adverse events (stroke, myocardial infarction, and coronary revascularization) at 3-year followup is reported in Table 4 .
Results from stratified analyses are shown in Figure 3 . Treatment effects in terms of 3-year mortality were similar across all subgroups.
Furthermore, a propensity score-adjusted analysis performed on the overall low-risk population showed that TAVI was associated with significantly lower 3-year survival than SAVR (P=0.002, hazard ratio =1.59, 95% confidence interval: 1.18-2.13); this result confirms the findings of the propensity score analysis performed on the matched groups (P=0.002, hazard ratio =1.70, 95% confidence interval: 1.22-2.37; Figure 3 ).
Discussion
The results of this study indicate that a rather large number of low-risk patients are treated by TAVI. The data from the OBSERVANT study suggest that the decision not to perform SAVR in such a large number of patients was made without any evident contraindication to conventional surgery. Indeed, the availability of information on the frailty status and on other important preoperative risk factors along with data on risk factors contraindicating SAVR made feasible the identification and matching of patients without prohibitive surgical risk. 
TAVI Compared With SAVR in Low-Risk Patients
Although there is not yet enough evidence on the efficacy of this approach, 17 the decision to offer TAVI to these patients was likely based on Institutional policies of choosing TAVI instead of SAVR even if this indication drift was not supported by clear evidence of any benefit in low-risk patients. Furthermore, the minimally invasive nature of TAVI is attractive in elderly patients, and we suspect that several lower-risk patients might have denied SAVR and asked to be treated by TAVI.
The present analysis demonstrated that either TAVI or SAVR can be performed with similar 30-day mortality and stroke. TAVI seems to offer a clear advantage in terms of reduction of acute kidney injury and need of blood transfusion, but it was associated with a higher risk of permanent pacemaker implantation, moderate-to-severe paravalvular regurgitation, vascular damage, and cardiac tamponade. The occurrence of paravalvular regurgitation and risk of permanent pacemaker implantation occurring after TAVI is of particular concern in low-risk patients. The risk of such complications may likely be reduced by the current transcatheter technology, 18 but still they may have negative prognostic implications in lowrisk patients in view of their longer expectancy of life. 3 This applies also to octogenarians without significant comorbidities because a pooled analysis of octogenarians undergoing SAVR, mostly from pre-TAVI era, showed that their 5-year survival is 65%. 19 The risk of complications typically associated with SAVR should be reduced as well by a strategy avoiding major bleeding through a minimally invasive approach and by decreasing myocardial ischemia time and duration of cardiopulmonary bypass using sutureless valves. 10 A few studies have previously reported on similar midterm outcome after TAVI and SAVR in patients with intermediate operative risk. [7] [8] [9] Another study reported on better operative survival with sutureless SAVR compared with TAVI. 10 However, these study populations still belong to a gray area of uncertainty. Taking into consideration that patients with such an operative mortality risk may have an even higher risk of significant postoperative adverse events, it is reasonable to justify a less-invasive approach in these intermediate-risk patients. On the contrary, patients randomized in the NOTION trial had a much lower operative risk (mean Society of Thoracic Surgeons score was ≈3%; mean EuroSCORE II was ≈2%), and the decision to perform TAVI in these patients should take into consideration the low risk of early adverse events occurring after SAVR and, even more importantly, the proven durability of conventional aortic valve prostheses. The present analysis included patients with an operative risk similar to that of NOTION patients, but opposite to the NOTION trial, subjects with coronary artery disease, on chronic dialytic treatment, with history of cardiac surgery and coronary revascularization, and prior stroke were not excluded in this subanalysis of the OBSERVANT study. Furthermore, the lack of power is a clear limitation of the NOTION trial. The observational nature, the limited exclusion criteria, and a longer follow-up are the main differences between the present analysis and the NOTION trial and, to some extent, may explain the differences in terms of survival of these 2 studies. However, both studies showed an increased risk of bleeding, cardiogenic shock, and acute kidney injury with SAVR and an increased risk of paravalvular regurgitation, permanent pacemaker implantation, and vascular complications with TAVI.
Current development of transcatheter technology focuses on facilitating rapid and accurate implantation of the prosthesis and on reducing the risk of vascular injury and paravalvular regurgitation. New transcatheter heart valve prostheses have been recently introduced and showed a potential for reducing such risks and may significantly improve the results of their predecessors. 20 Therefore, the present results may be affected by the disadvantages of using second-generation prostheses, and the value of next-generation prostheses in low-risk patients should be reassessed in the near future. 
Study Limitations
Several limitations related with this study should be acknowledged. First, OBSERVANT is a multicenter, prospective observational study, and the lack of randomization may introduce a selection bias. To compensate for the potential selection and evident baseline imbalance between the study groups, propensity score matching was performed and provided a well-balanced and rather large study population. The results of propensity score matching may still be biased by counfounders not taken into account in this analysis. However, the OBSERVANT is a prospective study including a quite large number of variables which are of significance in risk stratification of patients with aortic valve stenosis. Importantly, conditions contraindicating SAVR were collected prospectively, and these patients were excluded from this analysis. Furthermore, these findings were confirmed at subgroup analyses, which showed no significant interactions and an increased risk of mortality in patients without significant comorbidities. Second, we recognize that the definition of low operative risk among these patients can be difficult. We adopted a cut off of 4% for EuroSCORE II for defining low-risk patients because these are the patients who are currently accepted for SAVR. 21 Furthermore, early experience showed that EuroSCORE II seems to be accurate in predicting early mortality in patients undergoing SAVR. 21 Third, the outcomes were not defined according to the Valve Academic Research Consortium criteria. 22 The reason is that such definitions are specifically designed to define complications after TAVI and, therefore, may be misleading to illustrate complications after SAVR, likely resulting in their overestimation. Furthermore, the OBSERVANT study was started on before these guidelines were published. Fourth, the 3-year follow-up prevents conclusive results on the long-term durability of these methods in these low-risk patients. Fifth, the OBSERVANT registry does not contain data on antithrombotic regimens at discharge. This limitation prevents the analysis of stroke events at 3 years, which in this series occurred more frequently after TAVI than SAVR. Although the optimal antithrombotic therapy after TAVI is a matter of debate, oral anticoagulation is usually administered after SAVR with a bioprosthesis for at least 3 months followed by single antiplatelet therapy. In view of the recently reported subclinical valve thrombosis after TAVI, 23 we speculate that suboptimal antithrombotic therapy may partly explain the increased risk of stroke after TAVI herein observed. Finally, this analysis included only patients who underwent isolated SAVR or TAVI, and it is unknown whether these results also applies to patients requiring concomitant coronary revascularization.
Conclusions
The results of this multicenter observational study showed that in patients with low operative risk, TAVI and SAVR achieve comparable early survival, whereas TAVI increases the risk of paravalvular regurgitation and implantation of pacemaker. Furthermore, significantly better 3-year survival and freedom Incidence rates are computed as actuarial estimates at the specific time point and reported as percentage. IR indicates incidence rates; MACCE, major adverse cardiac and cardiovascular events (defined as the composite of death from any cause, stroke, acute myocardial infarction, and coronary revascularization); SAVR, surgical aortic valve replacement; and TAVI, transcatheter aortic valve implantation. Figure 3 . Analysis of the 3-year mortality in different subgroups of patients with testing for interaction. CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IR, incidence rate; LVEF, left ventricular ejection fraction; SAVR, surgical aortic valve replacement; and TAVI, transcatheter aortic valve implantation. TAVI Compared With SAVR in Low-Risk Patients from MACCE were observed after SAVR compared with TAVI. These results suggest that, at this stage, expanding the indications of TAVI toward lower-risk patients may not be justified. Because next generation transcatheter heart valve prostheses may decrease the risk of paravalvular regurgitation, permanent pacemaker implantation, and access site complications, further studies on the results with these new valve prostheses are necessary to support this approach in patients with low operative risk.
